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Background: MT1G inactivation mediated by promoter methylation has been reported in thyroid cancer. However,
the role of MT1G in thyroid carcinogenesis remains unclear. The aim of this study is to examine the biological
functions and related molecular mechanisms of MT1G in thyroid cancer.
Methods: Methylation-specific PCR (MSP) was performed to analyze promoter methylation of MT1G and its
relationship with clinicopathological characteristics of papillary thyroid cancer (PTC) patients. Conventional and
real-time quantitative RT-PCR assays were used to evaluate mRNA expression. The functions of ectopic MT1G
expression were determined by cell proliferation and colony formation, cell cycle and apoptosis, as well as cell
migration and invasion assays.
Results: MT1G expression was frequently silenced or down-regulated in thyroid cancer cell lines, and was also
significantly decreased in primary thyroid cancer tissues compared with non-malignant thyroid tissues. Promoter
methylation, along with histone modification, contributes to MT1G inactivation in thyroid tumorigenesis. Moreover,
our data showed that MT1G hypermethylation was significantly positively associated with lymph node metastasis in
PTC patients. Importantly, restoring MT1G expression in thyroid cancer cells dramatically suppressed cell growth and
invasiveness, and induced cell cycle arrest and apoptosis through inhibiting phosphorylation of Akt and Rb.
Conclusions: We have for the first time revealed that MT1G appears to be functional tumor suppressor involved in
thyroid carcinogenesis mainly through modulating the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and
partially through regulating the activity of Rb/E2F pathway in this study.
Keywords: Thyroid cancer, Metallothionein 1G (MT1G), DNA methylation, PI3K/Akt pathway, Rb/E2F pathwayBackground
Thyroid cancer is the most common malignant tumor in
endocrine system, and its incidence has been steadily in-
creasing in many regions of the world [1,2]. Follicular
epithelial cell-derived thyroid tumors are the most com-
mon type, accounting for about 95-97% of all thyroid
malignancies, and are histologically classified into fol-
licular adenoma (FA), papillary thyroid cancer (PTC),
follicular thyroid cancer (FTC), and anaplastic thyroid
cancer (ATC). PTC and FTC are differentiated thyroid
cancer as they possess differentiated features of their* Correspondence: phou@mail.xjtu.edu.cn
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reproduction in any medium, provided the ororigin cells and have a good prognosis. ATC is an ultim-
ate undifferentiated thyroid cancer with an inexorable
fatal outcome and generally fails to respond to available
chemo- and radiotherapy. Poorly differentiated thyroid
cancers (PDTCs) are those within intermediate histo-
pathological patterns between differentiated and undif-
ferentiated thyroid cancers [3,4].
Like other cancers, thyroid carcinogenesis involves grad-
ual accumulation of various genetic and epigenetic alter-
ations, leading to gain-of-function in oncogenes and loss-
of-function in tumor suppressor genes [5,6]. Expanded
knowledge of genetic events occurring in thyroid cancer
has improved our understanding of thyroid tumorigenesis
and provided new insights into thyroid cancer manage-
ment. Most of these events are closely bound up withThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kinase (PI3K)/Akt pathways, which are crucial for tumor
initiation and progression. For example, rearrangement of
RET/PTC and mutations of BRAF and RAS account for
approximately 70% of overactivation of MAPK signaling,
leading to PTC initiation, while the alterations affecting
PI3K/Akt pathway, such as mutations of RAS, PTEN and
PIK3CA, amplification of PIK3CA and rearrangement of
PAX8/PPARγ, are extensive in FTC. Despite of the initiat-
ing role in FTC, the coexistence of PI3K/Akt pathway-
related genetic alterations is also found to play a role
in facilitating progression and dedifferentiation in thy-
roid cancer [5,7,8].
In addition to genetic factors, epigenetic events, such
as aberrant promoter methylation, play a key role in hu-
man carcinogenesis [9], including thyroid cancer [6,10].
Promoter methylation is one of the major mechanisms
to inactivate tumor-related genes, particularly tumor
suppressor genes, along with genetic events, ultimately
leading to carcinogenesis [9,11]. Significantly, promoter
methylation is now regarded as an important hallmark
of cancer cells, and plays a significant role in tumor
transformation and progression, impacting the clinical
outcome of cancer patients [12,13].
Metallothionein 1G (MT1G), a member of Metallothioneins
(MTs), is a highly conserved, low-molecular weight (6–7
kDa), and cysteine residues-rich protein [14,15]. Most of
the biological functions proposed for MTs are related to
metal-binding property, including detoxification of heavy
metals, donation of zinc/copper to certain enzymes and
transcription factors and protection against oxidative
stress [16-18]. Previous studies showed that MT1G ex-
pression was repressed by promoter methylation in several
human cancers, including hepatocellular cancer, colorectal
cancer, prostate cancer and thyroid cancer [19-22]. More-
over, restoration of MT1G expression in thyroid cancer
cells inhibited cell growth in vitro and in vivo, suggesting
an oncosuppressor role [23]. However, the molecular
mechanisms underlying MT1G as a tumor suppressor in
thyroid cancer remain totally unknown. In the present
study, our data indicated that MT1G hypermethylation
was frequently found in PTC and significantly associated
with lymph node metastasis. Importantly, our data for the
first time revealed that ectopic expression of MT1G in
thyroid cancer cells dramatically inhibited cell growth and
invasiveness, and induced cell cycle arrest and apoptosis
via modulating the activity of PI3K/Akt pathway.
Methods
Clinical samples and DNA isolation
With the institution review board approval, a total of
244 paraffin-embedded thyroid tissues were randomly
obtained from the First Affiliated Hospital of Xi’an
Jiaotong University School of Medicine (Xi’an, P.R. China),including 178 PTCs, 16 FTCs, 9 medullary thyroid cancers
(MTCs), 9 ATCs, and 32 goiters. None of these patients
received chemotherapy or radiotherapy before the surgery.
Informed consent was obtained from each patient before
the surgery. All of the samples were histologically exam-
ined by a senior pathologist at Department of Pathology
of the Hospital to identify the clinicopathological charac-
teristics of the tumors, which were presented in Table 1.
The genomic DNA was isolated from paraffin-embedded
tissues as previously described [7], using xylene to re-
move the paraffin and sodium dodecyl sulfate (SDS)
and proteinase K to digest tissues, followed by stand-
ard phenol-chloroform extraction and ethanol precipi-
tation of DNA. Extraction of total RNA from paraffin-
embedded tissues was performed using E.Z.N.A. FFPE
RNA Kit (Omega Bio-Tek Inc., GA) according to manu-
facturers’ instruction.
Cell culture
Human thyroid cancer cell lines BCPAP, FTC133, IHH4,
K1, 8305C and the normal thyroid epithelial cell-derived
cell line HTori-3 were from Dr. Haixia Guan (The First
Affiliated Hospital of China Medical University, Shenyang,
P.R. China). C643 was from Dr. Lei Ye (Ruijin Hospital,
Shanghai, P.R. China). The origins and genetic alterations
of these thyroid cancer cells were summarized in (see
Additional file 1: Table S1). These cells were all routinely
cultured at 37°C in RPMI 1640 medium with 10% fetal bo-
vine serum (FBS), except for FTC133 that was cultured in
DMEM/Ham’s F-12 medium (Invitrogen Technologies,
Inc., CA). All media were supplemented with penicillin/
streptomycin. For some experiments, cells were treated
with DNA methyltransferase (DNMT) inhibitor 5-aza-
2′-deoxycytidine (5-Aza-dC) or/and histone deacetylase
(HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA)
as the indicated concentrations and time, and medium
and agents were replenished every 24 h. The powder
of 5-Aza-dC and SAHA were obtained from Sigma-
Aldrich and Cayman Chemical, and dissolved in 50%
acetic acid/50% PBS and DMSO, respectively. The same
volumes of the vehicle (50% acetic acid/50% PBS or
DMSO) were used as the controls.
RNA extraction, conventional RT-PCR and real-time
quantitative RT-PCR
Total RNA was extracted using TRIzol reagent (Takara
Inc., Dalian, P.R. China) according to the instructions of
manufacturer. one μg of total RNA was converted to
cDNA using PrimeScript RT reagent Kit (Takara Inc.,
Dalian, P.R. China) according to the instructions of the
manufacturer. Conventional RT-PCR was carried out to
amplify MT1G. The β-actin gene was run in parallel for
quality. PCR products were resolved by 1.5% agarose gel
electrophoresis and visualized by ethidium bromide
Table 1 Clinical profile of thyroid cancer patients and controls
Characteristics No. of patients (%)
PTC (n=178) FTC (n=16) MTC (n=9) ATC (n=9) Goiter (n=32)
Gender
Male 48 (27.0) 3 (18.8) 4 (44.4) 4 (44.4) 2 (6.3)
Female 130 (73.0) 13 (81.3) 5 (55.6) 5 (55.6) 30 (93.8)
Age (years, mean ± SD) 42.1 ± 15.3 49.5 ± 14.5 53.6 ± 9.5 65.6 ± 9.7 48.7 ±15.0
≤30 41 (23.0) 1 (6.3) 0 (0.0) 0 (0.0) 6 (18.8)
30-50 92 (51.7) 7 (43.8) 4 (44.4) 1 (11.1) 9 (28.1)
50-70 33 (18.5) 7 (43.8) 5 (55.6) 5 (55.6) 15 (46.9)
>70 12 (6.7) 1 (6.3) 0 (0.0) 3 (33.3) 2 (6.3)
Tumor size (cm3)*
≤1 19 (14.8) 3 (42.9) 0 (0.0) 0 (0.0)
1-3 34 (26.6) 1 (14.3) 0 (0.0) 1 (33.3)
3-5 25 (19.5) 0 (0.0) 0 (0.0) 0 (0.0)
>5 50 (39.1) 3 (42.9) 1 (11.1) 2 (66.7)
Tumor stage
I 109 (61.2) 6 (37.5) 1 (11.1) 0 (0.0)
II 25 (14.0) 3 (18.8) 2 (22.2) 0 (0.0)
III 43 (24.2) 7 (43.8) 6 (66.7) 0 (0.0)
IV 1 (0.6) 0 (0.0) 0 (0.0) 9 (100.0)
Invasion
No 98 (55.1) 11 (68.8) 6 (66.7) 3 (33.3)
Yes 80 (44.9) 5 (31.3) 3 (33.3) 6 (66.7)
Lymph node metastasis
No 92 (51.7) 13 (81.3) 2 (22.2) 6 (66.7)
Yes 86 (48.3) 3 (18.7) 7 (77.8) 3 (33.3)
Recurrence
No 158 (88.8) 11 (68.8) 7 (77.8) 6 (88.9)
Yes 20 (11.2) 5 (31.3) 2 (22.2) 3 (11.1)
*Only 140 patients have the information of tumor size.
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to evaluate the expression ofMT1G, E-cadherin,Vimentin,
Snail, Slug, and Twist on a CFX96 Thermal Cycler Dice™
real-time PCR system (Bio-Rad Laboratories, Inc., CA),
using SYBR Premix ExTaq II (Takara Inc., Dalian, P.R.
China) according to the instructions of manufacturer.
The expression value of each gene was normalized to
18S rRNA cDNA to calculate the relative amount of
RNA present in each sample according to the2-ΔΔCt
method [24]. Each sample was run in triplicate. The
primer sequences were presented in (see Additional
file 1: Table S2).
Sodium bisulfite treatment and methylation-specific
PCR (MSP)
Genomic DNA was treated with sodium bisulfite as de-
scribed previously [25]. Briefly, a final volume of 20 μLof H2O containing 2 μg genomic DNA, 10 μg salmon
sperm DNA, and 0.3M NaOH was incubated at 50°C for
20 min to denature the DNA. The mixture was then in-
cubated for 2 h at 70°C in 500 μL of a freshly prepared
solution containing 3 M sodium bisulfite (Sigma, Saint
Louis, MO) and 10 mM hydroquinone (Sigma, Saint
Louis, MO). DNA was subsequently purified with a
Wizard DNA Clean-Up System (Promega Corp.,
Madison, WI) following the instructions of the manu-
facturer, followed by ethanol precipitation, dry, and
resuspension in 50 μL of deionized H2O. Bisulfited-
treated DNA samples were stored at −80°C until use.
MSP was performed in a final reaction mixture of
20 μL containing 50 ng of bisulfite-treated DNA, 16.6
mM of ammonium sulfate, 67 mM of Tris (pH 8.8), 2
mM MgCl2, 200 μM each of deoxynucleotide triphos-
phate mixture (dATP, dCTP, dGTP, and dTTP), 200 nM
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DNA polymerase (Invitrogen Technologies, Inc., CA).
The PCR was run in a Thermal cycler (Bio-Rad Labora-
tories, Inc., CA) as follows: after a 4-min denaturation at
95°C, the reaction was run 35 cycles, each comprising
45 s of denaturing at 95°C, 45 s of annealing at vari-
able temperatures according to the primers, and 45 s
of extension at 72°C, with an extension at 72°C for 5 min
as the last step. Normal leukocyte DNA was methylated
in vitro with Sss I methylase (New England Biolabs,
Beverly, MA) to generate completely methylated DNA
as a positive control. Methylation-specific primers were:
5′- TCG TAT ACG GGG GGT ATA GC-3′ (forward) and
5′- GCG ATC CCG ACC TAA ACT -3′ (reverse), and
Unmethylation-specific primers were: 5′- AAGTTGTAT
ATGGGGGGTATAGT-3′ (forward) and 5′- CCCACA
ATCCCAACCTAAACT -3′(reverse). The PCR products
were electrophoresed on a 1.2 % agarose gel and visualized
under UV illumination.
Plasmid constructs and transfection
The full-length MT1G open reading frame was amplified
from human thyroid epithelial cell line HTori-3 by RT-
PCR, and cloned into mammalian expression vector
pEGFP-N1. Thyroid cancer cells were transfected with
pEGFP-N1-MT1G or pEGFP-N1 (empty vector) using
X-tremeGene HP DNA Transfection Reagent (Roche
Applied Science, Germany) according to the manufacturer’s
protocol. After 48 h of transfection, the transfectants were
selected in a medium containing 0.5 mg/mL of G418 for 2
to 3 weeks to generate the stable pools.
Western blot analysis
Cells were lysed in RIPA buffer. Cellular proteins
were collected and subjected to 10% SDS-PAGE, and
transferred onto PVDF membranes (Amersham Pharmacia
Biotech, Piscataway, NJ). The membranes were then
incubated with specific primary antibodies. Anti-
phospho-AktSer473, anti-phospho-AktThr308, anti-total-Akt
(t-Akt), and anti-phospho-Erk1/2 were purchased from
Bioworld Technology, co, Ltd. Anti-p53 and anti-Mdm2
were purchased from Santa Cruz Biotechnology, Inc.
Anti-E-cadherin, anti-Vimentin, anti-phospho-RbSer811
and anti-Rb were purchased from Epitomics, Inc.
Anti-Bak and anti-GAPDH were purchased from Abgent,
Inc. Anti-phospho-p70S6K was purchased from R&D
Systems, Inc. Anti-p21 was purchased from Cell Signaling
Technology, Inc. Anti-Smac was purchased from
Abcam. This was followed by incubation with horse-
radish peroxidase-conjugated anti-rabbit or anti-mouse
IgG antibodies from Santa Cruz Biotechnology, Inc.,
and antigen-antibody complexes were visualized using
the Western Bright ECL detection system (Advansta,
CA).Cell proliferation and colony formation assays
Cells stably transfected with pEGFP-N1-MT1G or empty
vector were plated in 96-well plates and cultured with
0.5% FBS. MTT assay was performed daily over a 4-d
time course to evaluate cell proliferation. Cell culture
was added with 10 μL of 5 mg/mL MTT agent (Sigma,
Saint Louis, MO) and incubated for 4 h, followed by
addition of 150 μL of DMSO and further 15-min incuba-
tion. The plates were then read on a microplate reader
using a test wavelength of 570 nm and a reference wave-
length of 670 nm. Three triplicates were done to deter-
mine each data point.
For colony formation assay, cells (5 × 105cells per well)
were seeded in 6-well plates and transfected with
pEGFP-N1-MT1G or empty vector. After 48 h, the
transfectants were replated in 12-well plate at a density
of 300 cells per well and subjected to G418 (500 μg/mL)
for 14 days. The selective medium was refreshed every 3
days. Surviving colonies (≥50 cells per colony) were fixed
with methanol, stained with 1.25% crystal violet and
counted under a light microscope. The experiments
were similarly performed in triplicate.
Cell cycle and apoptosis assays
For cell cycle analysis, transiently transfected cells were
harvested, washed twice in PBS, and fixed in 70% etha-
nol on ice for at least 30 min. Cells were then stained
with propidium iodide solution (50 μg/mL propidium
iodide, 50 μg/mL RNase A, 0.1% Triton-X, 0.1mM EDTA).
Cell cycles were analyzed based on DNA contents by
FACS using a Flow Cytometer (BD Biosciences, NJ).
Apoptosis assays were performed by the use of
Hoechst 33342 (Sigma-Aldrich, Saint Louis, MO) stain-
ing as previously described [26]. Briefly, transiently
transfected cells were stained with 10 μg/mL of Hoechst
33342 at 37°C for 30 min. After PBS washing, the
stained cells were imaged with a digital camera attached
to a fluorescence microscope (Olympus IX71). For quan-
titation of the number of apoptotic cells, 500 cells were
counted under microscope, and characteristic morph-
ology of apoptotic nuclei was defined as previously de-
scribed [27]. All the experiments were performed in
duplicate.
Cell migration and invasion assays
Cell migration and invasion assays were performed using
Transwell chambers (8.0 μm pore size; Millipore, MA),
which were coated with or without Matrigel (4 × dilu-
tion; 60 μL/well; BD Bioscience, NJ), in 24-well plates.
Chambers were pre-coated with rat tail tendon collagen
type 1 (0.5 mg/mL) on the lower surface. Cells stably
transfected with pEGFP-N1-MT1G or empty vector were
starved overnight and then seeded in the upper chamber
at a density of 2 × 105cells/mL in 400 μL of medium
Table 2 MT1G hypermethylation in PTC ― univariate
associations with clinicopathological characteristics
(OR1 and 95% CI)
Variable OR1 95% CI P value
Gender 0.99 0.48-2.01 0.97
Age2 0.92 0.63-1.36 0.69
Tumor invasion 0.71 0.38-1.36 0.31
Lymph node metastasis 2.14 1.12-4.07 0.02*
Tumor stage3 0.97 0.67-1.40 0.87
Tumor size4 1.11 0.78-1.58 0.55
Tumor recurrence 1.19 0.47-2.99 0.71
1OR: odds ratio with 95% confidence interval.
2Age (≤30y; 30-50y; 50-70y; >70y).
3Tumor stage (I, II, III, IV).
4Tumor size (≤1 cm; 1–3 cm; 3–5 cm; >5 cm).
*Significant at P <0.05.
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was added to the lower chamber. Following a 24 h-
incubation at 37°C with 5% CO2, non-migrating (or
non-invading) cells in the upper chamber were removed
with a cotton swab, and migrating (or invading) cells
were fixed in 100% methanol and stained with 0.5% crys-
tal violet in 2% ethanol. Photographs were taken ran-
domly for at least four fields of each membrane. The
number of migrating (or invading) cells was expressed as
the average number of cells per microscopic field over
four fields.
Scratch wound-healing assay
Cells were cultured in standard medium until they were
80-90% confluent on the day of transfection. After 48 h
of transfection, cells were starved by medium containing
0.5% serum overnight. The wounds were scratched using
200 μl sterile pipette tips. Cells were then cultured in
medium containing 1% serum to facilitate cell migration
into the wounded area. The widths of wound were mea-
sured and photographed under a phase-contrast micro-
scope. Each experiment was performed in triplicate wells
for three times.
Statistical analysis
The SPSS statistical package (16.0, Chicago, IL, USA)
was used for data analysis. Independent sample t and χ2
tests were used to analyze continuous and categorical vari-
ables, respectively. The risk of MT1G hypermethylation to
clinicopathological characteristics was analyzed using uni-
variate or multivariate logistic regression. All of the statis-
tical tests were two-sided. A P < 0.05 was considered to be
statistically significant.
Results
Frequent down-regulation and promoter
hypermethylation of MT1G in primary thyroid cancers
Similar to the findings in a previous study (23), MT1G
expression was significantly down-regulated in PTC tis-
sues compared with non-malignant tissues (P =0.0001)
(see Additional file 1: Figure S1A). It has been well doc-
umented that aberrant promoter methylation is related
to gene silencing. We next analyzed the methylation sta-
tus of MT1G by methylation-specific PCR (MSP). A typ-
ical CpG island spans the promoter region of MT1G,
and the position of MSP primers is indicated in (see
Additional file 1: Figure S1B). MT1G hypermathylation
was found in 30.2% (64/212) of thyroid cancers, includ-
ing 31.5% (56/178) of PTC, 25.0% (4/16) of FTC, 22.2%
(2/9) of MTC, and 22.2% (2/9) of ATC. In addition, it
was also found in 18.8% (6/32) of goiter. These data sug-
gested that MT1G was more frequently methylated in
thyroid cancer tissues compared with non-malignant
thyroid tissues (see Additional file 1: Table S3). MSPresults of 2 representative PTC samples were shown in
(see Additional file 1: Figure S1C).
Association of MT1G hypermethylation with lymph node
metastasis in PTC
Because frequent MT1G hypermethylation was demon-
strated in thyroid cancers, particularly in PTC, the associ-
ation of MT1G hypermethylation with clinicopathological
characteristics was analyzed in a total of 178 PTC. As
shown in Table 2, we failed to find a significant relation-
ship between MT1G hypermethylation and most of clini-
copathological characteristics, such as gender, age, tumor
invasion, tumor stage, tumor size, and tumor recurrence.
However, the univariate analysis revealed that MT1G
hypermethylation was associated with a significantly in-
creased risk of lymph node metastasis (OR =2.14,
95% CI =1.12-4.07; P =0.02). In order to assess the inde-
pendent association of MT1G hypermethylation with gen-
der, age, tumor invasion, lymph node metastasis, tumor
stage, and tumor recurrence, we further performed multi-
variate logistic regression. Similar to univariate analysis,
after adjustment, MT1G hypermethylation remained
significantly positively associated with lymph node
metastasis (OR=2.40, 95% CI=1.19-4.83) (see Additional
file 1: Table S4), suggesting that MT1G hypermethylation
might be an independent factor in predicting lymph node
metastasis for PTC patients.
Epigenetic silencing of MT1G in thyroid cancer cells
To determine whether MT1G expression is regulated by
epigenetic mechanisms in thyroid cancer, such as pro-
moter methylation and histone modification, we exam-
ined MT1G expression in 6 thyroid cancer cell lines by
conventional RT-PCR. As shown in Figure 1A (upper
panel), MT1G expression was silenced or down-regulated
in all thyroid cancer cell lines compared with normal thy-
roid epithelial cell line HTori3. MT1G hypermethylation
Figure 1 MT1G inactivation mediated by epigenetic alterations
in thyroid cancer. (A) Frequent down-regulation and promoter
methylation of MT1G in thyroid cancer cell lines. MT1G expression
was determined by semi-quantitative RT-PCR with β-actin as an
internal control (upper panel). Promoter methylation of MT1G in cell
lines was determined by MSP (lower panel). Mk, DNA marker; P,
positive control for methylated gene. (B) MT1G expression was
restored in thyroid cancer cells treated with 5-Aza-dC and SAHA
alone or in combination. Real-time quantitative RT-PCR was
performed to evaluate mRNA expression of MT1G, and 18S mRNA
was used as a normalized control. Data are presented as mean ± SD
of values from three different assays.
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that showed complete methylation (Figure 1A, lower
panel). However, down-regulation or silencing of MT1G
was not completely consistent with methylation status of
its promoter. For example, methylation level of MT1G
was not high in FTC133 cells, although its expression was
nearly undetected. Thus, we supposed that other epigen-
etic mechanisms, such as histone modification, along with
DNA methylation, were involved in MT1G inactivation in
thyroid cancer cells. To explore this, thyroid cancer cell
lines were treated with a DNMT inhibitor, 5-Aza-dC, and
a HDAC inhibitor, SAHA, alone or in combination.
MT1G expression was then analyzed using real-time
quantitative RT-PCR. As shown in Figure 1B, 5-Aza-dC
treatment only caused partial reactivation of MT1G in
most of cancer cell lines. Compared with 5-Aza-dC treat-
ment alone, MT1G expression was more significantly re-
stored in these cancer cells treated with SAHA alone or incombination with 5-Aza-dC. Of them, MT1G expression
was most significantly induced by these inhibitors in K1
cells. These data suggested that epigenetic alterations
would be a major mechanism to inactivate MT1G in thy-
roid cancer cells.
MT1G inhibits thyroid cancer cell growth
Frequent down-regulation or silencing of MT1G medi-
ated by epigenetic alterations in thyroid cancer cell lines
and primary thyroid cancers but not in non-malignant
thyroid tissues implicated that MT1G may be a tumor
suppressor. To test this speculation, we examined the
growth inhibitory effect through ectopic expression of
MT1G in K1, FTC133, BCPAP and C643 cells, wherein
MT1G expression was relatively low and could be dra-
matically induced by 5-Aza-dC and SAHA. MT1G re-
expression in the transfected cells was confirmed by
conventional and real-time quantitative RT-PCR, respect-
ively (see Additional file 1: Figure S2A). Ectopic expression
of MT1G caused a decrease in cell proliferation, par-
ticularly in K1 and FTC133 cells (see Additional file 1:
Figure S2B). The inhibitory effect on thyroid cancer cell
growth was further confirmed by colony formation
assay. As shown in (see Additional file 1: Figure S2C),
the colonies formed in MT1G-transfected cells were
fewer and smaller than those formed in empty vector-
transfected cells, particularly in K1 cells. Taken to-
gether, MT1G exhibits the growth inhibitory ability in
thyroid cancer cells and acts as a potential tumor
suppressor.
MT1G induces cell cycle arrest and apoptosis of thyroid
cancer cells
Suppression of cell growth in cancer cells is usually asso-
ciated with concomitant cell cycle arrest and activation
of cell death pathways. We therefore examined the con-
tribution of cell cycle arrest and apoptosis to the ob-
served growth inhibition of MT1G-transfected cells. As
shown in Figure 2, compared with empty vector, cell
cycle was arrested at the G1 phase when cells were
transfected with pEGFP-N1-MT1G. The percentage of
G1 phase was increased from 55.9% to 62.1% at 60 h
post-transfection, and from 59.1% to 65.9% at 84 h post-
transfection in K1 cells, and from 61.0% to 67.7% at 48 h
post-transfection, and from 62.4% to 68.0% at 72 h post-
transfection in FTC133 cells, respectively. In addition,
characteristic morphologies of apoptotic nuclei, such as
chromatin condensation, margination and nuclear
fragmentation, were more frequently observed in cells
transfected with pEGFP-N1-MT1G compared with
empty vector. As shown in Figure 3, the apoptotic cell
number increased in MT1G-transfected cells compared
with empty vector-transfected cells, particularly in K1
cells.
Figure 2 MT1G induced thyroid cancer cell cycle arrest. K1 and FTC133 cells transiently transfected with pEGFP-N1-MT1G or empty vector
were cultured for the indicated times. DNA content was measured by flow cytometry to determine cell cycle fractions. Representative flow
cytometric histograms of cells transfected with pEGFP-N1-MT1G and empty vector from three independent experiments were shown in left panel.
The fraction of cells in each cell cycle phase was indicated in right panel.
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In the present study, promoter methylation of MT1G was
shown to increase the risk of lymph node metastasis in
PTC patients. Thus, we next attempted to explore the ef-
fect of MT1G restoration on the migration and invasion
of thyroid cancer cells. As shown in Figure 4A, for K1
cells, there was a significantly lower number of migrated
cells in MT1G-transfected cells than empty vector-
transfected cells (P <0.01), indicating that MT1G inhibited
cancer cell migration. Furthermore, the Matrigel assays
showed that the number of cells that passed through
Matrigel-coated membrane into the lower chamber wassignificantly lower in MT1G-transfected K1 cells than
empty vector-transfected K1 cells (P <0.001, Figure 4B).
Cell migration and invasion assays were also performed in
FTC133 cells using the same protocols. However, we failed
to find any migrating or invading cells in bothMT1G- and
empty vector-transfected cells. Thus, scratch wound-
healing assay was performed to evaluate cell migration in
FTC133 cells. As shown in Figure 4C, the wound healing
was markedly inhibited inMT1G-transfected cells as com-
pared to empty vector-transfected cells. These observa-
tions suggest that MT1G inhibits the invasive potential of
thyroid cancer cells.
Figure 3 MT1G induced thyroid cancer cell apoptosis. K1 and FTC133 cells were transiently transfected with pEGFP-N1-MT1G or empty
vector. After 48 h post-transfection, apoptotic cells were determined by Hoechst 33342 staining and observed under a fluorescent microscope.
Selective apoptotic nuclei showing characteristics of apoptosis, including chromatin margination, condensation, and fragmentation, were
indicated by arrows. Relative percentage of apoptotic cells in the MT1G-transfected and empty vector-transfected groups was presented in right
panel. *, P <0.05.
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To gain insights into the downstream signaling pathways
modulated by MT1G in tumor inhibition, we investi-
gated the effect of MT1G on the activities of PI3K/Akt
and MAPK pathways, which play a key role in cell pro-
liferation and survival in human cancers, including thy-
roid cancer [5]. Our data showed that ectopic expression
of MT1G inhibited phosphorylation of Akt in both K1
and FTC133 cells (Figure 5A). However, we did not find
its effect on phosphorylation of Erk1/2 (data not shown).
Next, we investigated the effect of MT1G on the expres-
sion of Mdm2, which can be regulated by the PI3K/Akt
pathway [28-30]. As also shown in Figure 5A, we indeed
observed that MT1G restoration decreased Mdm2 ex-
pression in thyroid cancer cells. It is well known that
PI3K/Akt pathway can influence the activity and stability
of tumor suppressor p53 through phosphorylation of
Mdm2 [28-31]. Thus, we investigated the effect of
MT1G on the p53 signaling pathways. As shown in
Figure 5B, restoring MT1G expression increased the
activity and stability of p53, and the expression of its
downstream targets, including p21, Bak and Smac, in
K1 cells. However, this phenomenon was not found
in FTC133 cells because TP53 gene is mutated in this
cell line (see Additional file 1: Table S1), leading to p53 in-
activation. These findings suggest that MT1G induces cell
cycle arrest and apoptosis at least partially mediated byp53 signaling pathway. Collectively, MT1G inhibits thy-
roid cancer cell growth mainly through regulating PI3K/
Akt signaling pathway (Figure 6).
To explore the molecular mechanism of MT1G con-
tributing to thyroid cancer cell migration and invasion,
we investigated the effect of MT1G on expression of E-
cadherin and Vimentin, the altered expressions of which
are hallmarks of epithelial-mesenchymal transition (EMT)
allowing epithelial cells to separate from their neighbors
and migrate to distant regions during tumor development
[32]. As shown in Figure 5C, E-cadherin expression was
dramatically up-regulated in the MT1G-transfected cells
compared with empty vector-transfected cells. However,
Vimentin expression was not significantly influenced by
MT1G restoration. Additionally, we determined the
mRNA expression of E-cadherin, Vimentin, and the tran-
scription suppressors of E-cadherin, including Snail, Slug,
and Twist in K1 and FTC133 cells. As shown in (see
Additional file 1: Figure S3), the expression of these
genes was not significantly different between MT1G-
transfected cells and empty vector-transfected cells,
suggesting that MT1G regulated E-cadherin expres-
sion at the post-transcriptional level. Taken together,
our data suggest that MT1G inhibits cell migration
and invasion by increasing the stability of E-cadherin
(Figure 6).
Notably, we observed that MT1G slightly inhibited
phosphorylation of tumor suppressor Rb, which plays a
Figure 4 MT1G inhibited the migration and invasion of thyroid cancer cells. K1 cells stably transfected with pEGFP-N1-MT1G or empty
vector were starved overnight and then seeded in the Transwell chambers without Matrigel for migration assay (A), and coated with Matrigel for
invasion assay (B), respectively. Following a 24 h-culture, non-migrating (or non-invading) cells in the upper chamber were removed and
migrating (or invading) cells were stained and calculated in four microscopic fields per sample. Shown are representative images of migrating
(or invading) cells (left panels). The bar graphs (right panels), corresponding to left panels, show means ± SD of the numbers of migrating
(or invading) cells from three independent experiments. **, P <0.01; ***, P <0.001. (C) FTC133 cells were transfected with pEGFP-N1-MT1G or
empty vector. After 48 h of post-transfection, the scratch wound-healing assay was performed to evaluate the effect of MT1G on cell migration.
Representative images of cell migration of FTC133 cells in scratch wound-healing assay were shown in left panel. The bar graphs show means ±
SD. of gap width of wounds at the indicated times from three independent experiments (right panel). *, P <0.05.
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the MT1G-transfected cells as compared to empty vector-
transfected cells (Figure 5D), suggesting that MT1G might
play a role in the control of cell proliferation partially
through modulating the activity of Rb/E2F pathway
(Figure 6).
Discussion
In the present study, we found that MT1G expression
was frequently absent or down-regulated in thyroid can-
cer cell lines, and was also significantly decreased in pri-
mary thyroid cancer tissues compared with non-malignant
thyroid tissues, which was consistent with the previous
studies [22,23]. These findings suggested thatMT1G wouldbe a candidate tumor suppressor in the pathogenesis of
thyroid cancer. The reduced expression ofMT1G is closely
associated with promoter methylation, as confirmed by
MSP assays and pharmacological DNA demethylation
treatment in the present study and a previous study [23],
implicating DNA methylation as a regulatory mechanism
ofMT1G inactivation in thyroid cancer. However, although
there was a higher prevalence of MT1G hypermethylation
in thyroid cancer tissues than in non-malignant thyroid tis-
sues, the difference was not significant, which was consist-
ent with a previous study in hepatocellular cancer [19].
Thus, we speculated that other epigenetic mechanisms
such as histone modification, along with DNA methyla-
tion, may contribute to MT1G inactivation in thyroid
Figure 5 MT1G inhibited the activity of PI3K/Akt pathway and phosphorylation of tumor suppressor Rb in thyroid cancer cells. Thyroid
cancer cell lines K1 and FTC133 stably transfected with pEGFP-N1-MT1G or empty vector were starved overnight and harvested. Cell lysates were
collected and subjected to Western blotting assays. (A) The antibodies against phospho-AktSer473 (p-Akt), total-Akt (t-Akt), and Mdm2 were used
to determine the effect of MT1G on the activity of PI3K/Akt signaling. (B) The effect of MT1G on the p53 signaling pathway was determined by
blotting p53 and its downstream targets, p21, Bak and Smac. (C) The expression of E-cadherin and Vimentin were used to evaluate the effect of
MT1G on cell migration and invasion. (D) The antibody against phospho-RbSer811 (p-Rb) was used to determine the effect of MT1G on the Rb/E2F
signaling. Shown in the lower portion of the panel is a quantitative illustration of levels of p-Rb protein using densitometry to measure the
density of the corresponding bands on Western blot shown in the upper portion of the panel. GAPDH was used for quality control of
Western blotting.
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cer cells with a histone deacetylase inhibitor, SAHA, alone
or in combination with 5-Aza-dC to explore the role of
histone deacetylation in regulating MT1G expression. Our
data showed that SAHA dramatically induced MT1G ex-
pression in thyroid cancer cells, suggesting that histone
deacetylation may be another crucial mechanism of MT1G
inactivation in thyroid cancer.
Down-regulation or silencing of MT1G might abolish
tumor suppression so as to contribute to thyroid tumori-
genesis. We thus tested the putative tumor suppressor
function of MT1G in human thyroid cancer cells. MT1G
restoration in thyroid cancer cells showed significant
growth-suppressing effect by inhibiting cell proliferation
and colony formation in the present study. In line with
this finding, a previous study demonstrated that cell
growth was inhibited in MT1G-reexpressed cells by both
in vitro and in vivo assays [23]. Our data also showed
that MT1G re-expression induced cell cycle arrest and
apoptosis, further supporting its tumor suppressor func-
tion. Of note, MT1G hypermethylation significantly in-
creased the risk of lymph node metastasis in PTC patients,
as supported by our findings that MT1G restorationdramatically inhibited the migration and invasion of thy-
roid cancer cells.
Although the evidence has highlighted the importance
of MT1G as an oncosuppressor in thyroid cancer, the
precise molecular mechanisms remain largely unclear.
To better understand the tumor suppressive effect of
MT1G in thyroid tumorigenesis, we investigated the ef-
fect of MT1G on the activities of two major signaling
pathways in thyroid cancer, including the PI3K/Akt and
MAPK pathways. These two pathways are involved in
propagation of signals from various cell membrane re-
ceptor tyrosine kinases into the nucleus, and regulate
multiple cell processes, including cell proliferation, dif-
ferentiation, and survival [5,35,36]. Our data showed that
ectopic expression of MT1G strongly inhibited phos-
phorylation of Akt, but not Erk1/2, in thyroid cancer
cells, suggesting that MT1G may play its tumor suppres-
sor role through modulating the activity of PI3K/Akt
pathway.
To explore the mechanism of MT1G contributing to
induction of cell cycle arrest and apoptosis, we tested
the effect of MT1G on p53 signaling pathways. Our find-
ings showed that MT1G restoration increased the stability
Figure 6 Schematic diagram of MT1G as a tumor suppressor in
thyroid cancer cells through regulating the PI3K/Akt and Rb/
E2F pathways. MT1G restoration inhibited phosphorylation of Akt,
leading to inhibition of cell growth. MT1G decreased Mdm2
expression through inhibiting the activity of Akt kinases. MT1G
increased the stability of p53 and E-cadherin by the decreased
ubiquitination of Mdm2, contributing to induction of cell cycle
arrest and apoptosis and suppression of cell migration and invasion.
MT1G also influenced cell growth, such as cell cycle progression and
cell death, through inhibiting phosphorylation of Rb.
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cluding p21, Bak, and Smac, in K1 cells, but not in
FTC133 cells. Of the genes transcriptionally regulated by
p53, p21WAF/CIP1 acts as a necessary mediator for the p53-
mediated G1 arrest [37]. Bak, involving in p53-mediated
mitochondrial apoptosis, is a pro-apoptotic Bcl-2 family
protein which induces the release of apoptogenic factors,
such as cytochrome c or Smac/DIABLO [38,39]. These
data demonstrated that the effect of MT1G on cell cycle
and cell death might be at least partially attributed to p53-
mediated cell cycle arrest and apoptosis. With the consid-
eration of decreased expression of Mdm2 induced by
MT1G, the up-regulation of p53 is most likely caused by
the reduced ubiquitination of Mdm2. Mdm2 functions as
an E3 ubiquitin ligase, involving in eukaryotic protein deg-
radation via ubiquitin proteasome system [40]. It de-
creases the stability of p53 by binding to its N-terminal
transactivation domain (TAD), and therefore, stimulating
its polyubiquinated degradation [41]. The previous studies
provide strong evidences that active Akt binds to and
phosphorylates Mdm2 at Ser166 and Ser186 to enhance
protein stability. Furthermore, phosphorylated Mdm2
translocates more efficiently to the nucleus, where it can
bind p53, resulting in enhanced p53 degradation [28-30].This was supported by our findings that MT1G restor-
ation inhibited phosphorylation of Akt and the expression
of Mdm2, further contributing to increased stability of
p53.
In the present study, we found that MT1G
hypermethylation was an independent risk factor for
lymph node metastasis in PTC. To be consistent with
this, the previous studies showed the association of
MT1G hypermethylation with poor prognosis in prostate
cancer, hepatoblastoma and colorectal cancer [20,21,32].
Thus, we supposed that MT1G may play a role in the
migration and invasion of thyroid cancer cells. Delight-
edly, our data showed that MT1G restoration increased
E-cadherin expression, resulting in the inhibition of mi-
gration and invasion in thyroid cancer cells. Decreased
expression of E-cadherin is a critical molecular event of
epithelial-mesenchymal transition (EMT), which endows
the epithelial cells with fibroblast-like properties and
shows reduced intercellular adhesion and increased mo-
tility [32]. In oncogenic process, multiple signal trans-
duction pathways may induce EMT. MAPK pathway, for
example, has been shown to activate two transcription
factors Snail and Slug, both of which are transcriptional
repressors of E-cadherin [42,43]. Twist, another tran-
scription factor, also induces loss of E-cadherin-mediated
cell-cell adhesion and EMT [44]. However, our data
showed that MT1G restoration did not affect the expres-
sion of these genes, suggesting MT1G-mediated E-
cadherin up-regulation at a posttranscriptional level. A
previous study revealed a novel role of Mdm2 in inter-
action with E-cadherin leading to its ubiquitination and
degradation, which promotes cell motility and invasive-
ness [45], as supported by our findings that MT1G
inhibited phosphorylation of Akt and the expression of
Mdm2, ultimately contributing to increased stability of
E-cadherin.
It is now clear that the Rb/E2F pathway is critical in
regulating the initiation of DNA replication and plays
a key role in controlling cell growth in human carcino-
genesis [33]. We also found that MT1G re-expression
slightly inhibited phosphorylation of Rb in the present
study, implicating the effect of MT1G on cell growth
at least partially through modulating the activity of
Rb/E2F pathway. This finding was supported by a re-
cent study that SM22α overexpression activated the
Rb/E2F pathway through elevating MT1G expression
in human hepatocarcinoma cells [46].
Conclusions
In summary, our data showed that MT1G acted as a
tumor suppressor, which was frequently inactivated by
epigenetic alterations, such as promoter methylation and
histone modification, in thyroid cancer.MT1G contributes
to suppression of thyroid carcinogenesis by inhibiting cell
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and apoptosis mainly through modulating the PI3K/Akt
signaling pathway and partially through regulating the Rb/
E2F pathway.
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